|

Defective (Recalled) Drugs
|
Baycol
Cerivastatin sodium or "Baycol"
is a synthetic pharmaceutical that belongs to a class of drugs
called statins. Unlike the other statins, Baycol use frequently
leads to a condition called rhabdomyolysis that has caused more
than one hundred deaths and hundreds of serious injuries.
[read
more] |
 |
|
|
Oxycontin
Purdue Pharma introduced the
painkiller Oxycontin into the U.S. market in
1995. It was marketed as a better way to control chronic,
debilitating pain,
since its time-release component enabled it to be administered in
larger
dosages to eliminate pain for a longer period of time than other
painkillers.
[read
more] |
 |
|
|
Fen-Phen
Manufactured by American Home
Products, Fen-Phen was once hailed as a wonder diet drug. It was
both quick and effective in combating obesity for
millions of users around the world. In the United States alone, an
estimated 1.1 million people were prescribed this combination of
diet drugs...
[read
more] |
 |
|
|
Rezulin
In March of 1997, Warner-Lambert
Company introduced Rezulin as the newest drug on the market for
the treatment of type 2 adult onset diabetes. U.S. Food and Drug
Administration approval followed an extraordinary accelerated
six-month review, making Rezulin the fastest-approved diabetes
pill in the nation...
[read
more] |
 |
|
|
Stadol
Stadol is a nasal spray form of
pain killer, intended to be used for migraine headaches. Because
Bristol-Myers Squibb, the manufacturer, claimed there was an
extremely low potential for abuse, the FDA allowed physicians to
prescribe Stadol without government control...
[read
more] |
 |
|
|
Serzone
Serzone is an
anti-depressant. Unfortunately Serzone has been linked to
liver failure. According to the manufacturer the rate of
liver failure associated with Serzone use is about 3-4 times
than greater than non-users....
[read
more] |
|
Levaquin
In 1997, Levaquin was introduced in the United States. Although the package insert carried the typical standard quinolone warning, it also indicated that in clinical trials, tendon injury occurred in less than 1 percent of all patients. The Levaquin label did not warn nor recommend to modify or decrease strenuous activities while taking Levaquin to decrease the chance of tendon injury.
[read
more] |
| |
|
|
|